Abbott Laboratories

ABT Healthcare Medical Devices

Abbott Laboratories' revenue for fiscal 2025 (year ended December 2025) was $44.3 billion, up 5.67% from fiscal 2024.

Revenue
+14.5%
EPS
−43.6%
Free cash flow
+28.9%
Total debt
+142.7%

Quarter to September 2026, against a year earlier

110.08 3.52 −3.10%
Market cap
$196.6B
P/E
42.3×
Fwd P/E
35.1×
Dividend yield
2.22%
F-score
5/9
Altman Z
5.61
Beneish M
−2.50
Dividend safety
62/100
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16
P/E ratio
33.68 14.79 33.70 28.03 35.72 43.80 42.17 54.38 226.12 41.99
Piotroski F-Score
5 7 6 6 8 6 7 7 4 5
P/S ratio
4.92 4.69 4.77 4.40 5.80 5.61 4.81 4.16 3.73 2.77
Altman Z-Score
5.61 5.27 5.04 4.85 5.53 4.34 3.83 3.34 2.36 2.79
Altman Z″-Score (non-manufacturers)
4.85 4.72 4.24 4.19 4.06 3.39 3.05 2.99 2.85 5.16
P/FCF ratio
29.50 30.99 37.78 24.61 28.89 33.91 34.14 25.92 23.07 27.70
Beneish M-Score
(2.50) (2.09) (2.47) (2.68) (2.66) (2.56) (2.59) (2.71) (2.05) (2.95)
P/Operating CF
65.80 68.62 62.92 82.59 81.45 51.11 63.56 72.04 62.37 49.30
Dividend Safety Score
62 — — — — — — — — —
P/B ratio
4.13 4.11 4.92 5.21 6.93 5.88 4.91 4.14 3.29 2.78
EV/Sales
5.01 4.84 4.95 4.55 5.98 5.94 5.25 4.66 4.40 2.86
EV/EBITDA
19.89 20.21 20.42 17.09 21.53 23.67 22.18 20.47 21.90 13.11
EV/FCF
30.04 31.96 39.24 25.46 29.79 35.90 37.21 29.03 27.15 28.62
Current Ratio
1.58 1.67 1.64 1.63 1.85 1.72 1.44 1.62 2.26 4.02
Net Debt/EBITDA
0.36 0.61 0.76 0.57 0.65 1.31 1.83 2.20 3.29 0.42
Debt/Equity
0.25 0.29 0.38 0.45 0.50 0.56 0.57 0.63 0.89 1.00
ROE
12.96% 30.91% 15.11% 19.01% 20.49% 13.98% 11.89% 7.66% 1.84% 6.66%
ROA
7.76% 17.33% 7.75% 9.27% 9.57% 6.40% 5.46% 3.30% 0.74% 2.98%
ROIC
8.87% 7.89% 8.76% 12.01% 12.02% 7.54% 6.28% 4.96% 1.99% 8.36%
Return on Tangible Assets
30.61% 66.49% 30.15% 36.69% 35.19% 25.59% 28.71% 17.96% 2.53% 5.42%
Average Days of Receivables
65.29 60.25 59.74 51.99 54.97 67.65 62.07 61.86 69.95 56.85
Earnings Yield
2.97% 6.76% 2.97% 3.57% 2.80% 2.28% 2.37% 1.84% 0.44% 2.38%
Free Cash Flow Yield
3.39% 3.23% 2.65% 4.06% 3.46% 2.95% 2.93% 3.86% 4.34% 3.61%
Free Cash Flow per Share
4.25 3.65 2.91 4.45 4.87 3.23 2.54 2.79 2.55 1.41
Book value per Share
30.31 27.53 22.31 21.05 20.30 18.61 17.70 17.48 17.87 14.03
Free Cash Flow
7,395.00 6,351.00 5,059.00 7,804.00 8,648.00 5,724.00 4,498.00 4,906.00 4,435.00 2,082.00
EV/EBIT
27.58 29.74 30.65 23.76 30.58 38.36 36.93 39.02 76.98 19.69
Other line items

Show all line items

Columns are period end dates · fundamentals updated 2 Nov 2026